Down-regulation of MET, the receptor for hepatocyte growth factor

被引:0
|
作者
Dean E Hammond
Sylvie Urbé
George F Vande Woude
Michael J Clague
机构
[1] Physiological Laboratory,
[2] University of Liverpool,undefined
[3] Van Andel Research Institute,undefined
来源
Oncogene | 2001年 / 20卷
关键词
Met; hepatocyte growth factor; endocytosis; proteasome;
D O I
暂无
中图分类号
学科分类号
摘要
The ligand-dependent degradation of activated tyrosine kinase receptors provides a means by which mitogenic signalling can be attenuated. In many cell types the ligand-dependent degradation of the tyrosine kinase receptor Met is completely dependent on the activity of the 26S proteasome (Jeffers et al., 1997b). We now show that degradation also requires trafficking to late endosomal compartments and the activity of acid dependent proteases as determined by the effects of a dominant negative form of dynamin (K44A) and a vacuolar-ATPase inhibitor, concanamycin. We show that in the presence of the proteasome inhibitor lactacystin, Met fails to redistribute from the plasma membrane to intracellular compartments. This observation is most consistent with the interpretation that proteasome activity is required for Met internalization and only indirectly for its degradation.
引用
收藏
页码:2761 / 2770
页数:9
相关论文
共 50 条
  • [31] Cortaictin overexpression inhibits ligand-induced down-regulation of the epidermal growth factor receptor
    Timpson, P
    Lynch, DK
    Schramek, D
    Walker, F
    Daly, RJ
    CANCER RESEARCH, 2005, 65 (08) : 3273 - 3280
  • [32] Down-regulation of a novel form of fibroblast growth factor receptor 1 in human breast cancer
    C Yiangou
    H Cox
    GS Bansal
    R Coope
    JJ Gomm
    R Barnard
    J Walters
    N Groome
    S Shousha
    RC Coombes
    CL Johnston
    British Journal of Cancer, 1997, 76 : 1419 - 1427
  • [33] The siRNA-Mediated Down-Regulation of Vascular Endothelial Growth Factor Receptor1
    Sani, Moslem Jafari
    Yazdi, Foad
    Karimi, Masoomeh Masoomi
    Alizadeh, Javad
    Rahmati, Majid
    Mahmudabadi, Ali Zarei
    IRANIAN RED CRESCENT MEDICAL JOURNAL, 2016, 18 (04)
  • [34] Down-regulation of a novel form of fibroblast growth factor receptor 1 in human breast cancer
    Yiangou, C
    Cox, H
    Bansal, GS
    Coope, R
    Gomm, JJ
    Barnard, R
    Walters, J
    Groome, N
    Shousha, S
    Coombes, RC
    Johnston, CL
    BRITISH JOURNAL OF CANCER, 1997, 76 (11) : 1419 - 1427
  • [35] DESENSITIZATION OF CULTURED GLIAL-CELLS TO EPIDERMAL GROWTH-FACTOR BY RECEPTOR DOWN-REGULATION
    HELDIN, CH
    WESTERMARK, B
    WASTESON, A
    NATURE, 1979, 282 (5737) : 419 - 420
  • [36] ROLES OF HEPATOCYTE GROWTH FACTOR/SCATTER FACTOR AND THE MET RECEPTOR IN THE EARLY DEVELOPMENT OF THE METANEPHROS
    WOOLF, AS
    KOLATSIJOANNOU, M
    HARDMAN, P
    ANDERMARCHER, E
    MOORBY, C
    FINE, LG
    JAT, PS
    NOBLE, MD
    GHERARDI, E
    JOURNAL OF CELL BIOLOGY, 1995, 128 (1-2): : 171 - 184
  • [37] The roles of hepatocyte growth factor scatter factor and Met receptor in human cancers (Review)
    To, CTT
    Tsao, MS
    ONCOLOGY REPORTS, 1998, 5 (05) : 1013 - 1024
  • [38] Hepatocyte growth factor and c-met/hepatocyte growth factor receptor in pulmonary adenocarcinomas: An evaluation of their expression as prognostic markers
    Takanami, I
    Tanana, F
    Hashizume, T
    Kikuchi, K
    Yamamoto, Y
    Yamamoto, T
    Kodaira, S
    ONCOLOGY, 1996, 53 (05) : 392 - 397
  • [39] DOWN-REGULATION OF EPIDERMAL GROWTH-FACTOR RECEPTORS BY DITHRANOL
    KEMENY, L
    MICHEL, G
    ARENBERGER, P
    RUZICKA, T
    ACTA DERMATO-VENEREOLOGICA, 1993, 73 (01) : 37 - 40
  • [40] TIME-RELATED RECOVERY OF HEPATOCYTE PGE2 RECEPTOR DOWN-REGULATION
    ROBERTSON, RP
    GARRITY, MJ
    CLINICAL RESEARCH, 1985, 33 (04): : A851 - A851